Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 386

1.

Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series.

Lemasson J, Cuzzubbo S, Doucet L, Gounant V, Baroudjian B, Herms F, Carpentier AF, Lebbé C, Vitaux H, Hautefort C, Delyon J; PATIO group.

Eur J Cancer. 2019 Jul 3;117:116-118. doi: 10.1016/j.ejca.2019.05.022. [Epub ahead of print] No abstract available.

PMID:
31279302
2.

Challenges in the diagnosis of primary cutaneous CD30+ anaplastic large-cell lymphoma.

Dobos G, Battistella M, Jouenne F, Mourah S, Vignon-Pennamen MD, Ram-Wolff C, Herms F, Dauendorffer JN, Rivet J, Cayuela JM, Bouaziz JD, Brice P, Lebbé C, Bagot M, de Masson A.

Br J Dermatol. 2019 Jul 6. doi: 10.1111/bjd.18328. [Epub ahead of print]

PMID:
31278742
3.

Discoidin Domain Receptors: A promising target in melanoma.

Reger de Moura C, Battistella M, Sohail A, Caudron A, Feugeas JP, Podgorniak MP, Pages C, Mazouz Dorval S, Marco O, Menashi S, Fridman R, Lebbé C, Mourah S, Jouenne F.

Pigment Cell Melanoma Res. 2019 Jul 4. doi: 10.1111/pcmr.12809. [Epub ahead of print]

PMID:
31271515
4.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
5.

Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas.

Dumont M, Ram-Wolff C, Roelens M, Brice P, de Latour RP, Battistella M, Madelaine I, Delyon J, Herms F, Bouaziz JD, Moins-Teisserenc H, Lebbé C, Bagot M, de Masson A.

Br J Dermatol. 2019 Jun 17. doi: 10.1111/bjd.18215. [Epub ahead of print]

PMID:
31206589
6.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV.

N Engl J Med. 2019 Jun 4. doi: 10.1056/NEJMoa1904059. [Epub ahead of print]

PMID:
31166680
7.

Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC).

Lebbe C, Garbe C, Stratigos AJ, Harwood C, Peris K, Marmol VD, Malvehy J, Zalaudek I, Hoeller C, Dummer R, Forsea AM, Kandolf-Sekulovic L, Olah J, Arenberger P, Bylaite-Bucinskiene M, Vieira R, Middleton M, Levy A, Eggermont AM, Battistella M, Spano JP, Grob JJ, Pages C; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2019 Jun;114:117-127. doi: 10.1016/j.ejca.2018.12.036. Epub 2019 May 13.

PMID:
31096150
8.

Severe Gastrointestinal Toxicity of MEK Inhibitors.

Mourad N, Lourenço N, Delyon J, Eftekhari P, Bertheau P, Allayous C, Ballon A, Pagès C, Allez M, Lebbé C, Baroudjian B; PATIO group.

Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000618. [Epub ahead of print]

PMID:
31095035
9.

Acquired generalized lipodystrophy under immune checkpoint inhibition.

Haddad N, Vidal-Trecan T, Baroudjian B, Zagdanski AM, Arangalage D, Battistella M, Gautier JF, Lebbe C, Delyon J; PATIO group.

Br J Dermatol. 2019 May 11. doi: 10.1111/bjd.18124. [Epub ahead of print]

PMID:
31077337
10.

Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.

Vallet A, Oriano B, Mortier L, Dalle S, Dutriaux C, Guillot B, Leccia MT, Dalac S, Saiag P, Lacour JP, Legoupil D, De Quatrebarbes J, Brunet-Possenti F, Lesimple T, Arnault JP, Aubin F, Granel-Brocard F, Stoebner PE, Maubec E, Dreno B, Allayous C, Porcher R, Lebbé C; for MelBase.

JAMA Dermatol. 2019 May 1. doi: 10.1001/jamadermatol.2019.0425. [Epub ahead of print]

PMID:
31042256
11.

Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis.

Tedbirt B, De Pontville M, Branger P, Picard C, Baroudjian B, Lebbé C, Carpentier AF, Delyon J; PATIO group.

Eur J Cancer. 2019 May;113:72-74. doi: 10.1016/j.ejca.2019.03.006. Epub 2019 Apr 12. No abstract available.

PMID:
30986705
12.

Usefulness of the 'two-step method' of digital follow-up for early-stage melanoma detection in high-risk French patients: a retrospective 4-year study.

Gasparini G, Madjlessi N, Delyon J, Carmisciano L, Brahimi N, Basset-Seguin N, Oren M, Battistella M, Lebbé C, Herms F, Baroudjian B.

Br J Dermatol. 2019 Apr 12. doi: 10.1111/bjd.18006. [Epub ahead of print] No abstract available.

PMID:
30977907
13.

RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor.

Jouenne F, De Moura CR, Lorillon G, Meignin V, Dumaz N, Lebbe C, Mourah S, Tazi A.

Ann Oncol. 2019 Apr 12. pii: mdz125. doi: 10.1093/annonc/mdz125. [Epub ahead of print] No abstract available.

PMID:
30977771
14.

Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.

Duverger L, Osio A, Cribier B, Mortier L, De Masson A, Basset-Seguin N, Lebbé C, Battistella M.

Cancer Immunol Immunother. 2019 Jun;68(6):951-960. doi: 10.1007/s00262-019-02334-8. Epub 2019 Apr 5.

PMID:
30953116
15.

Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years.

Basse C, Italiano A, Penel N, Mir O, Chemin C, Toulmonde M, Duffaud F, Le Cesne A, Chevreau C, Maynou C, Anract P, Gouin F, Rios M, Firmin N, Kurtz JE, Kerbrat P, Piperno-Neumann S, Bertucci F, Rosset P, Isambert N, Bompas E, Dubray-Longeras P, Fiorenza F, Le Maignan C, Chaigneau L, Thyss A, Bouché O, Eymard JC, Delcambre Lair C, Adam J, Karanian M, Lebbé C, Dupré A, Meeus P, Brahmi M, Dufresne A, Ducimetière F, Ray-Coquard I, Blay JY.

Int J Cancer. 2019 Mar 28. doi: 10.1002/ijc.32307. [Epub ahead of print]

PMID:
30924137
16.

Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.

Tétu P, Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Dalac S, Dutriaux C, Lacour JP, Saiag P, Brunet-Possenti F, De Quatrebarbes J, Stoebner PE, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Dreno B, Mohamed S, Ballon A, Porcher R, Lebbe C.

Eur J Cancer. 2019 May;112:38-46. doi: 10.1016/j.ejca.2019.02.009. Epub 2019 Mar 22.

PMID:
30909072
17.

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.

Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A.

Eur J Cancer. 2019 May;112:29-31. doi: 10.1016/j.ejca.2019.01.015. Epub 2019 Mar 21. No abstract available.

PMID:
30903870
18.

Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study.

Delyon J, Rabate C, Euvrard S, Harwood CA, Proby C, Güleç AT, Seçkin D, Del Marmol V, Bouwes-Bavinck JN, Ferrándiz-Pulido C, Ocampo MA, Barete S, Legendre C, Francès C, Porcher R, Lebbe C; Skin Care in Organ Transplant Patients Europe (SCOPE) group.

J Am Acad Dermatol. 2019 Aug;81(2):448-455. doi: 10.1016/j.jaad.2019.03.028. Epub 2019 Mar 19.

PMID:
30902727
19.

A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors.

Louveau B, Delyon J, De Moura CR, Battistella M, Jouenne F, Golmard L, Sadoux A, Podgorniak MP, Chami I, Marco O, Caramel J, Dalle S, Feugeas JP, Dumaz N, Lebbe C, Mourah S.

Oncotarget. 2019 Mar 1;10(18):1669-1687. doi: 10.18632/oncotarget.26707. eCollection 2019 Mar 1.

20.

Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients.

Gauci ML, Boudou P, Squara PA, Delyon J, Allayous C, Mourah S, Resche-Rigon M, Lebbé C, Baroudjian B, Gautier JF; PATIO group.

Melanoma Res. 2019 Jun;29(3):328-332. doi: 10.1097/CMR.0000000000000585.

PMID:
30817442

Supplemental Content

Loading ...
Support Center